{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:30:22Z","timestamp":1792855822133,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"DOI":"10.1186\/s13550-025-01250-6","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T18:11:02Z","timestamp":1746555062000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Quantitative 177Lu-DOTATATE SPECT\/CT is predictive of 6-month PRRT morphological response in midgut neuroendocrine tumors: a pilot study"],"prefix":"10.1186","volume":"15","author":[{"given":"Iness","family":"Megherbi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Hoog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Perrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedia","family":"Brixi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cadiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hoeffel-Fornes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8738-4841","authenticated-orcid":false,"given":"David","family":"Morland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"issue":"7","key":"1250_CR1","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, \u00d6berg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844\u201360.","journal-title":"Ann Oncol"},{"issue":"2","key":"1250_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"issue":"5","key":"1250_CR3","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","volume":"40","author":"L Bodei","year":"2013","unstructured":"Bodei L, Mueller-Brand J, Baum RP, Pavel ME, H\u00f6rsch D, O\u2019Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(5):800\u201316.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1250_CR4","doi-asserted-by":"crossref","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3).","DOI":"10.1093\/jnci\/92.3.205"},{"key":"1250_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.radonc.2019.09.003","volume":"141","author":"R Sharma","year":"2019","unstructured":"Sharma R, Wang WM, Yusuf S, Evans J, Ramaswami R, Wernig F, et al. 68Ga-DOTATATE PET\/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours. Radiother Oncol. 2019;141:108\u201315.","journal-title":"Radiother Oncol"},{"issue":"2","key":"1250_CR6","doi-asserted-by":"publisher","first-page":"236","DOI":"10.2967\/jnumed.123.265987","volume":"65","author":"M Mileva","year":"2024","unstructured":"Mileva M, Marin G, Levillain H, Artigas C, Van Bogaert C, Marin C, et al. Prediction of 177Lu-DOTATATE PRRT outcome using multimodality imaging in patients with gastroenteropancreatic neuroendocrine tumors: results from a prospective phase II LUMEN study. J Nucl Med. 2024;65(2):236\u201344.","journal-title":"J Nucl Med"},{"issue":"10","key":"1250_CR7","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1007\/s00259-023-06257-6","volume":"50","author":"R Alipour","year":"2023","unstructured":"Alipour R, Jackson P, Bressel M, Hogg A, Callahan J, Hicks RJ, et al. The relationship between tumour dosimetry, response, and overall survival in patients with unresectable neuroendocrine neoplasms (NEN) treated with 177Lu DOTATATE (LuTate). Eur J Nucl Med Mol Imaging. 2023;50(10):2997\u20133010.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"1250_CR8","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1007\/s00259-022-05792-y","volume":"49","author":"A Sygu\u0142a","year":"2022","unstructured":"Sygu\u0142a A, Ledwon A, Hasse-Lazar K, Jurecka-Lubieniecka B, Michalik B, Paliczka-Cie\u015blik E, et al. In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2022;49(11):3841\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"19","key":"1250_CR9","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.1158\/1078-0432.CCR-18-0947","volume":"24","author":"A Yordanova","year":"2018","unstructured":"Yordanova A, Wicharz MM, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, et al. The role of adding somatostatin analogues to peptide receptor radionuclide therapy as a combination and maintenance therapy. Clin Cancer Res. 2018;24(19):4672\u20139.","journal-title":"Clin Cancer Res"},{"key":"1250_CR10","unstructured":"lutathera-epar-product. -information_en.pdf [Internet]. [cited 2024 Feb 27]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lutathera-epar-product-information_en.pdf"},{"issue":"1","key":"1250_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2967\/jnumed.115.159012","volume":"57","author":"M Ljungberg","year":"2016","unstructured":"Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sj\u00f6green-Gleisner K. MIRD pamphlet 26: joint EANM\/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy. J Nucl Med. 2016;57(1):151\u201362.","journal-title":"J Nucl Med"},{"issue":"6","key":"1250_CR12","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","volume":"49","author":"K Sj\u00f6green Gleisner","year":"2022","unstructured":"Sj\u00f6green Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49(6):1778\u2013809.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1250_CR13","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s00259-022-06028-9","volume":"50","author":"JC Dickson","year":"2023","unstructured":"Dickson JC, Armstrong IS, Gabi\u00f1a PM, Denis-Bacelar AM, Krizsan AK, Gear JM, et al. EANM practice guideline for quantitative SPECT-CT. Eur J Nucl Med Mol Imaging. 2023;50(4):980\u201395.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1250_CR14","doi-asserted-by":"publisher","first-page":"109683","DOI":"10.1016\/j.radphyschem.2021.109683","volume":"188","author":"EJ Chen","year":"2021","unstructured":"Chen EJ, Safwan Selvam HS, Tan TH, Chew MT. Quantitative analysis of xQuant reconstruction algorithm in SPECT\/CT. Radiat Phys Chem. 2021;188:109683.","journal-title":"Radiat Phys Chem"},{"key":"1250_CR15","doi-asserted-by":"publisher","first-page":"102611","DOI":"10.1016\/j.ejmp.2023.102611","volume":"112","author":"C Hoog","year":"2023","unstructured":"Hoog C, Verrecchia-Ramos E, Dejust S, Lalire P, Sezin G, Moubtakir A, et al. Implementation of xSPECT, xSPECT bone and broadquant from literature, clinical survey and innovative Phantom study with task-based image quality assessment. Phys Med. 2023;112:102611.","journal-title":"Phys Med"},{"key":"1250_CR16","doi-asserted-by":"crossref","unstructured":"Mahajan S, O\u2019Donoghue J, Weber W, Bodei L. Integrating Early Rapid Post-peptide Receptor Radionuclide Therapy Quality Assurance Scan into the Outpatient Setting. J Nucl Med Radiat Ther [Internet]. 2019 [cited 2024 Jun 8];10(1). Available from: https:\/\/www.omicsonline.org\/open-access\/integrating-early-rapid-postpeptide-receptor-radionuclide-therapy-quality-assurance-scan-into-the-outpatient-setting-2155-9619-1000395-107659.html","DOI":"10.4172\/2155-9619.1000395"},{"issue":"1","key":"1250_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40658-024-00658-8","volume":"11","author":"L Vergnaud","year":"2024","unstructured":"Vergnaud L, Dewaraja YK, Giraudet AL, Badel JN, Sarrut D. A review of 177Lu dosimetry workflows: how to reduce the imaging workloads? EJNMMI Phys. 2024;11(1):65.","journal-title":"EJNMMI Phys"},{"issue":"1","key":"1250_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40658-024-00620-8","volume":"11","author":"S Ha","year":"2024","unstructured":"Ha S, Kim YI, Oh JS, Yoo C, Ryoo BY, Ryu JS. Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT\/CT in patients with metastatic neuroendocrine tumour. EJNMMI Phys. 2024;11(1):14.","journal-title":"EJNMMI Phys"},{"issue":"4","key":"1250_CR19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s11307-014-0806-4","volume":"17","author":"JC Sanders","year":"2015","unstructured":"Sanders JC, Kuwert T, Hornegger J, Ritt P. Quantitative SPECT\/CT imaging of (177)Lu with in vivo validation in patients undergoing peptide receptor radionuclide therapy. Mol Imaging Biol. 2015;17(4):585\u201393.","journal-title":"Mol Imaging Biol"},{"key":"1250_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13550-018-0443-z","volume":"8","author":"DMV Huizing","year":"2018","unstructured":"Huizing DMV, de Wit-van BJ, Verheij M, Stokkel MPM. Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review. EJNMMI Res. 2018;8:89.","journal-title":"EJNMMI Res"},{"issue":"10","key":"1250_CR21","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.2967\/jnumed.124.267964","volume":"65","author":"O Tuncer","year":"2024","unstructured":"Tuncer O, Steinberger D, Steiner J, Hinojos M, Rhee SY, Humphrey B, et al. Quantitative SPECT\/CT metrics in early prediction of [177 Lu]Lu-DOTATATE treatment response in gastroenteropancreatic neuroendocrine tumor patients. J Nucl Med. 2024;65(10):1584\u201390.","journal-title":"J Nucl Med"},{"issue":"12","key":"1250_CR22","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.3390\/diagnostics10121059","volume":"10","author":"D Calabr\u00f2","year":"2020","unstructured":"Calabr\u00f2 D, Argalia G, Ambrosini V. Role of PET\/CT and therapy management of pancreatic neuroendocrine tumors. Diagnostics (Basel). 2020;10(12):1059.","journal-title":"Diagnostics (Basel)"},{"issue":"8","key":"1250_CR23","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/00006231-200208000-00005","volume":"23","author":"T Belhocine","year":"2002","unstructured":"Belhocine T, Foidart J, Rigo P, Najjar F, Thiry A, Quatresooz P, et al. Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67. Nucl Med Commun. 2002;23(8):727\u201334.","journal-title":"Nucl Med Commun"},{"issue":"11","key":"1250_CR24","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1200\/JCO.2008.16.0861","volume":"27","author":"T Terasawa","year":"2009","unstructured":"Terasawa T, Lau J, Bardet S, Couturier O, Hotta T, Hutchings M, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin\u2019s lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27(11):1906\u201314.","journal-title":"J Clin Oncol"},{"key":"1250_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2021.01.008","volume":"146","author":"V Ambrosini","year":"2021","unstructured":"Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer. 2021;146:56\u201373.","journal-title":"Eur J Cancer"},{"issue":"9","key":"1250_CR26","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","volume":"44","author":"MF Bozkurt","year":"2017","unstructured":"Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET\/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur J Nucl Med Mol Imaging. 2017;44(9):1588\u2013601.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1250_CR27","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/MPA.0000000000000846","volume":"46","author":"JR Howe","year":"2017","unstructured":"Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, et al. The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the North American neuroendocrine tumor society. Pancreas. 2017;46(6):715\u201331.","journal-title":"Pancreas"},{"issue":"1","key":"1250_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40644-020-00335-w","volume":"20","author":"DMV Huizing","year":"2020","unstructured":"Huizing DMV, Aalbersberg EA, Versleijen MWJ, Tesselaar MET, Walraven I, Lahaye MJ, et al. Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy. Cancer Imaging. 2020;20(1):57.","journal-title":"Cancer Imaging"},{"issue":"7","key":"1250_CR29","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/bjc.2013.103","volume":"108","author":"S Vinjamuri","year":"2013","unstructured":"Vinjamuri S, Gilbert TM, Banks M, McKane G, Maltby P, Poston G, et al. Peptide receptor radionuclide therapy with 90Y-DOTATATE\/90Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity. Br J Cancer. 2013;108(7):1440\u20138.","journal-title":"Br J Cancer"},{"issue":"13","key":"1250_CR30","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","volume":"26","author":"DJ Kwekkeboom","year":"2008","unstructured":"Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]Octreotate: toxicity, efficacy, and survival. JCO. 2008;26(13):2124\u201330.","journal-title":"JCO"},{"issue":"Suppl 1","key":"1250_CR31","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):S122\u201350.","journal-title":"J Nucl Med"},{"issue":"9","key":"1250_CR32","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.2967\/jnumed.110.075002","volume":"51","author":"AR Haug","year":"2010","unstructured":"Haug AR, Auernhammer CJ, W\u00e4ngler B, Schmidt GP, Uebleis C, G\u00f6ke B, et al. 68Ga-DOTATATE PET\/CT for the early prediction of response to somatostatin Receptor\u2013Mediated radionuclide therapy in patients with Well-Differentiated neuroendocrine tumors. J Nucl Med. 2010;51(9):1349\u201356.","journal-title":"J Nucl Med"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01250-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-025-01250-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01250-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T18:11:04Z","timestamp":1746555064000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-025-01250-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1250"],"URL":"https:\/\/doi.org\/10.1186\/s13550-025-01250-6","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the ethical standards as laid down in the Declaration of Helsinki and its later amendments. This study was declared and registered on the Health Data Hub in conformity with the reference methodology MR004 of the \u201cCommission Nationale de l\u2019Informatique et des Libert\u00e9s\u201d, allowing the computerized management of medical data (MR004 n\u00b016730359; CNIL n\u00b02213791). The participants were informed of the possibility of using the information concerning them and had a right of opposition. Written informed consent was obtained from all participants. According to french law, no formal institutional review board approval or ethics committee is required for this type of study, based on patient files.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}